**Name of Journal:** *World Journal of Gastroenterology*

**Manuscript NO:** 63525

**Manuscript Type:** MINIREVIEWS

**Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis**

Moran S *et al*. Minimal hepatic encephalopathy

Segundo Moran, Marlene López-Sánchez, María del Pilar Milke-García, Gustavo Rodríguez-Leal

**Segundo Moran, Marlene López-Sánchez, Gustavo Rodríguez-Leal,** Laboratory of Hepatology Research, Centro Médico Nacional, Siglo XXI, Mexican Institute of Social Security, Mexico City 06720, Mexico

**María del Pilar Milke-García,** Division of Nutrition, National Institute of Nutrition, Salvador Zubirán, Mexico City 14080, Mexico

**Author contributions:** Moran S and López M contributed to the conception and design; López M, Moran S, Milke P, and Rodriguez Leal contributed to the analyses and data interpretation; Moran S, López M, and Milke P drafted the article; Moran S, López M, Milke P, and Rodriguez Leal G contributed to critical revision of the article for important intellectual content; López M, Moran S, Milke P, and Rodriguez Leal contributed to the final version of the article.

**Supported by** theMexican Institute of Social Security, No. FFIS/IMSS/PROT/G16/1589; and National Council for Science and Technology (CONACYT), No. SALUD-2014-C01-233823.

**Corresponding author: Segundo Moran, PhD, Doctor,** Laboratory of Hepatology Research, Centro Médico Nacional, Siglo XXI, Mexican Institute of Social Security, Cuauhtemoc 330, Mexico City 06720, Mexico. segundomoran@hotmail.com

**Received:** January 28, 2021

**Revised:** April 1, 2021

**Accepted:** April 21, 2021

**Published online:**

**Abstract**

Minimal hepatic encephalopathy (MHE) corresponds to the earliest stage of hepatic encephalopathy (HE). MHE does not present clinically detectable neurological-psychiatric abnormalities but is characterized by imperceptible neurocognitive alterations detected during routine clinical examination *via* neuropsychological or psychometrical tests. MHE may affect daily activities and reduce job performance and quality of life. MHE canincrease the risk of accidents and may develop into overt encephalopathy, worsening the prognosis of patients with liver cirrhosis. Despite a lack of consensus on the therapeutic indication, interest in finding novel strategies for prevention or reversion has led to numerous clinical trials; their results are the main objective of this review. Many studies address the treatment of MHE, which is mainly based on the strategies and previous management of overt HE. Current alternatives for the management of MHE include measures to maintain nutritional status while avoiding sarcopenia, and manipulation of intestinal microbiota with non-absorbable disaccharides such as lactulose, antibiotics such as rifaximin, and administration of different probiotics. This review analyzes the results of clinical studies that evaluated the effects of different treatments for MHE.

**Key Words:** Minimal hepatic encephalopathy; Sarcopenia; Probiotics; Non-absorbable disaccharides, Rifaximin; L-ornithine-L-aspartate

Moran S, López-Sánchez M, Milke-García MDP, Rodríguez-Leal G. Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis. *World J Gastroenterol* 2021; In press

**Core Tip:** Minimal hepatic encephalopathy (MHE) is a frequent complication in patients with liver cirrhosis. MHE affects the quality of life and increases the risk of falls and car accidents, worsening patients’ prognoses; however, there is no standard of care. Current alternatives for the management of MHE include measures to maintain the nutritional status while avoiding sarcopenia, manipulation of intestinal microbiota with non-absorbable disaccharides such as lactulose, antibiotics such as rifaximin, and administration of different probiotics. This review analyzes the results of clinical studies that evaluated the effects of different treatments for MHE.

**INTRODUCTION**

Minimal hepatic encephalopathy (MHE) corresponds to the earliest stage of hepatic encephalopathy (HE) (Table 1) and is characterized by imperceptible neurocognitive alterations detected during routine clinical examination through neuropsychological or psychometrical tests[1-3]. The prevalence of MHE in patients with liver cirrhosis varies from 23.7% to 56.6%, depending on the diagnostic criteria and studied population[4-8]. MHE predisposes patients to the development of overt HE (OHE)[9-11]; it has been reported that 50% of patients with MHE develop OHE within 3 years[12]. MHE may also affect daily activities, negatively reduce job performance and quality of life (QOL),and increase the risk of causing car accidents[6,13,14].

**ASSESSMENT OF MHE**

Despite the existence of several grading instruments that allow for the distinction of patients with MHE among those without neurocognitive alterations, there are no specific tests that discriminate the different grades of covert HE (CHE). Table 2 shows some of the tools used for the diagnosis of MHE. Although formal neuropsychological assessment is the best method to identify neurocognitive deficits, there is no standard battery for MHE recognition, so neuropsychologists must interpret and assess these tests. Therefore, other neuropsychological, computerized, and short neuropsychological batteries have been suggested for its identification[15-17].

Even when surveillance of MHE is possible in every patient with liver cirrhosis, a screening that enables us to distinguish patients at risk of suffering from or causing car accidents among active drivers or distinguish patients manifesting cognitive deterioration or noticeable low job performance has been suggested[15].

**ASSOCIATED CLINICAL CONDITIONS**

Certain conditions that have been addressed as contributors to the development of MHE and are therefore considered potential therapeutic targets. They are as follows.

***Hyperammonaemia***

The increase in arterial ammonia has been found in patients manifesting some signs of cerebral dysfunction such as mild lethargy, brisk deep tendon reflexes, or increased resistance to passive arm movement[18], and in patients with the specific diagnosis of MHE[19-23] including those with concomitant MHE and sarcopenia[7,23]. An increase in the production of ammonia may be related to dysbiosis, small intestinal [bacterial overgrowth](about:blank) (SIBO), or *Helicobacter pylori* infection as a result of increased activity of bacterial urease, intestinal urea hydrolysis, and absorption of nitrogenous products[20,24]. This, together with decreased intestinal motility and altered integrity of the intestinal barrier, facilitate the increase in bacterial translocation and endotoxin release to the circulation[25,26].

***Sarcopenia***

A low skeletal muscle index (SMI) is found in 58% of patients with liver cirrhosis; however, its prevalence increases to 84% in patients with MHE compared to patients without MHE, of which 17-30% are sarcopenic[7,21,23]. In all, 41% to 49% of patients with MHE show muscle depletion according to a mid-arm muscle circumference (MAMC) and triceps skinfold thickness (TSF) below the 5th percentile and a decreased muscle function[7,21]. Protein malnutrition is associated with MHE; 49% of these patients are undernourished compared to 28-30% of patients without cognitive alterations[7].

***SIBO***

The concurrence of SIBO is greater in patients with MHE (38.6-65.4%) than in those without neurocognitive deterioration (8.8%-16.13%)[22,25-27].

***Dysbiosis***

An association of specific bacterial species and HE has been suggested[28,29]. An increase in *Enterobacteriaceae* (*Escherichia coli)* and *Staphylococcus spp.* has been related to MHE,and nearly 22% of patients with cirrhosis and MHE have *H. pylori* infection[20,29].

***Inflammatory factors***

Interleukin 6 (IL-6), IL-17a, and IL-18 cytokine concentrations are increased in cirrhotic patients with alterations in the psychometric tests but with no clinical manifestations of HE[30-32].

***Hyponatremia***

In all, 31% of patients with MHE have hyponatremia compared to 16% of patients without neurocognitive alterations[7].

**CLINICAL TRIALS FOR TREATMENT OF MHE**

There has been a striking increase of studies addressing the treatment of MHE, which is mainly based on the strategies and previous management of OHE. Tables 3-5 evaluate strategies aimed toward achieving greater detoxification and lower production of ammonia***.***

**STRATEGIES TO INCREASE THE DETOXIFICATION OF AMMONIA**

***Energy-protein intake***

The rationale for increasing the caloric and protein intake for the treatment of MHE (30-45 kcal/kg/d and 1.2-1.5 g protein/kg/d, respectively) considers the association of the neurocognitive alterations and sarcopenia in patients with MHE, together with the enhancement of ammonia detoxification by preserving muscle mass and avoiding protein malnutrition[7,33-36]. Only in one of these studies was the protein intake set to provide 1.0-1.5 g/kg/d for the treatment of MHE; this protein was solely of vegetable origin[33].

In patients without previous HE, the reversion of MHE upon normoprotein diet implementation (1.0-1.5 g/kg of ideal body weight/d) was attested to in 57.8% of the patients after 4 wk of dietary treatment. The response rate further increased to 68.4% by week 8; however, neither dietary compliance nor other factors possibly related to the reversion such as amino acid supplementation or use of lactulose and/or antibiotics were assessed. Moreover, results were not compared against a control group[37].

Regarding the effect of ammonia concentration, a dietary intake of at least 1 g vegetable protein/kg/d and 30 kcal/kg/d reported an average change of ˗6.53 µmol ammonia/L *vs* the basal concentrations after 6 mo of treatment[33].An average decrease of 20.8 µmol ammonia/L with respect to the basal concentration was achieved with the administration of branched-chain amino acids (0.25 g/kg/d) and a standardized diet (35 kcal/kg/d and 1 g of protein/kg/d); however, patients were also receiving lactulose at the time of the study[34]. These dietary modifications have also improved some of the sarcopenia indicators, such as TSF and handgrip values in patients with MHE receiving dietary counseling; this study does not report what these values were before the study was started[33].

In some studies, a starting diet is standardized according to the minimum energy and protein requirements before the implementation of a specific treatment; however, dietary compliance was not measured in any of the aforementioned studies (Tables 3-5).

***L-ornithine-L-aspartate***

This compound provides substrates to metabolic pathways involved in the detoxification of ammonia by stimulating both the urea synthesis and glutamine synthesis[38]. The administration of L-ornithine-L-aspartate (LOLA) improved MHE in 35% of the patients, 47% with lactulose, 35% with VSL#3 probiotic, and 10% with a placebo during a 3-mo treatment (Table 3)[39]. The administration of LOLA also showed a 11.42% improvement in the mean critical flicker frequency threshold (CFF) after 8 wk of treatment[40]. Ammonia decreased an average of 8.94% compared to the initial concentrations in patients who were treated with an infusion of LOLA for just 7 d; however, nausea was a side effect in 15% of the patients[41].

**STRATEGIES TO REDUCE THE PRODUCTION OF AMMONIA**

***Fiber supplementation***

Dietary fiber as a prebiotic is a non-digestible food component that has a positive effect by stimulating the growth and activity of the colon bacteria. The addition of insoluble fiber may potentiate the effects of disaccharides through acidification of the colonic lumen by the process of fermentation, which in turn, decreases the production of ammonia[42]. The increase in dietary fiber has been proposed as an alternative for the treatment of patients with MHE (Table 3); reversion of MHE has been reported in 50% of patients treated with symbiotics and fermentable fibers or simply fermentable fibers and in only 13% of patients treated with placebo[29].

***Probiotics/symbiotics***

The beneficial effects of the administration of probiotics and symbiotics on different variables related to MHE have been confirmed (Table 3). The mechanisms of action include displacement of gas-forming bacteria, inhibition of pathogenic bacteria adhesion, modulation of the immune response, and microbiota modification through the colonic acidification following fiber fermentation[43]. The colonization of the intestine by probiotics that compete against ammonia-producing microorganisms and the concomitant use of probiotics and prebiotics (symbiotics) may cause synergistic effects on the host by decreasing the colonic pH *via* fermentation and less colonization of ammonia-producing bacteria, resulting in decreased ammonemia[29].

Following a 60-d trial of consuming a probiotic yogurt, 70.58% of the patients with MHE reversed this condition, and none did in the control group. Despite having assessed treatment compliance in the probiotic yogurt group, this was not done in the control group nor were other dietary components controlled that could have affected the results[44]. The administration of VSL#3 led to reversion of MHE in 35% of patients and 10% in the placebo group after 3 mo of treatment[40]; after 8 wk of treatment, normalization of the CFF values were achieved in 8.68% of patients in the treatment group *vs* 2.28% in the placebo group[40].

The supplementation of symbiotics (*Pediacoccus pentoseceus* 5-33:3, *Leuconostoc mesenteroides* 32-77:1, *Lactobacillus paracasei* subspecies *paracasei* 19, and *Lactobacillus plantarum* 2592, and fermentable fiber; inulin, pectin, beta glucan, and resistant starch) for 1 mo decreased the mean ammonia 36.1% with respect to the mean basal concentrations, while treatment with fermentable fibers decreased this mean 34.7% in the same period; placebos only decreased this mean concentration in 3.14%[29]. Furthermore, when the basal values of endotoxins were considered in these three groups, a mean reduction was achieved in 24.7%, 38.89%, and 4.5%, respectively[29]. Similar results could be observed after 90 d of treatment with *Bifidobacterium longum* and fructooligosaccharides, where the mean decrease in ammonemia was 42.69% with respect to the basal concentration and 10.44% in the placebo group[45].

The importance of treating MHE underscores the possibility of avoiding a future OHE episode. In patients with liver cirrhosis without previous HE episodes and treated prophylactically with VSL#3 for a 3-mo period, the number needed to treat (NNT) for the group of patients with MHE was 5 *vs* 13 in those without MHE to avoid an OHE episode[46].

***Non-absorbable disaccharides***

In most of the studies on patients with MHE, the effects of lactulose have also been assessed (Table 4). The mechanisms of action of this synthetic disaccharide are mainly related to its cathartic effects, which allow for the reduction of intestinal transit, and therefore, the content of toxic compounds in its lumen and absorption. Along its colonic transit, lactulose is metabolized by bacteria, decreasing the colonic pH.This in turn, renders a hostile environment to urease-producing bacteria together with the increased growth of *Lactobacillae* and *Bifidobacteriae*, which reduce ammonia production in the colonic lumen and interfere with its absorption and that of other nitrogenous compounds produced in the intestine[45,47].

A 4-wk treatment with lactulose enables reversion of MHE in 54.2% of patients compared to 12% in the control group[48]; after 60 d of treatment, the reported reversion increased up to 69.5% in the lactulose group *vs* 21.4% in the placebo group in a per protocol analysis set[49]. Reversion after a 3-mo treatment with lactulose is estimated at 47.5% and 10% in the group receiving the placebo[39].

The treatment of MHE with lactulose also decreases the mean ammonia concentration an approximate 23.03%-32.25% after 1 mo of treatment and 28.66% with the concomitant use of probiotics and lactulose[48,50]. In another study where patients with MHE were followed for 2 mo, the mean decrease of ammonia was 22.1% considering the basal concentrations of the treated group; there was also an increase in 10.46% in the placebo group, *p* < 0.001[51]. Treatment of lactulose for 3 mo achieved a decrease between 23% and 79% considering the basal ammonia concentrations, rendering an average decrease of 63.16 µmol/L[49,52-54]. When the decrease was analyzed as a categoric variable, the improvement rate in the ammonia concentration in 14 patients was attested to in 6/7 of them (85.7%) when lactulose was administered *vs* 4/7 (57.4%) when patients were treated with lactose[55]. Another change observed after administration of lactulose in patients suffering from MHE has been the decrease in mean basal concentrations of inflammatory factors such as tumor necrosis factor alpha (17.29%), IL-6 (29.54%), IL-18 (32.14%), and endotoxins (36.76%) after a 3-mo treatment[52].

After the use of lactulose for 3 mo, positive changes in some variables related to sleeping such as total sleeping time, sleep efficiency, sleep latency, awake time, and latency rapid eye movement were found[54]. According to some tools that measure QOL such as the sickness impact profile, there is improvement in the overall score and within each of the categories after lactulose administration; however, the study does not describe if any of the patients had alterations in their QOL at the time of being included in the study[49,56].

When endpoints such as the prevention of an OHE episode were considered, patients with liver cirrhosis and no previous HE episode who were treated prophylactically with lactulose for a year showed a decreased incidence; however, the impact of the treatment was greater in those having MHE (NNT in no MHE patients: 50; NNT in MHE patients: 5)[57].

Certain characteristics of patients with MHE lead to lack of response to lactulose treatment. These include hyponatremia, which is prevalent among 50% of the non-responders, and a high basal ammonia concentration[58].

Some alterations that may be detected at the beginning of the treatment with lactulose are diarrhea, flatulence, abdominal bloating, distaste for lactulose, and nausea[11,48,55,59,60]. Diarrhea and flatulence may be reduced after adjusting the lactulose dose[60].

***Non-absorbable antibiotics***

Rifaximin is a non-absorbable antibiotic that modifies the abundance of bacteria and the intestinal bacterial metabolism. The administration of rifaximin in patients with MHE (Table 5) improves consciousness and decreases the degree of endotoxemia[61]. Rifaximin further reduces ammonemia and improves the psychometric tests more than non-absorbable disaccharides[59].

Use of rifaximin for 2 and 12 wk led to reversion of HE in 52.63% and 73.7%, respectively, while the group treated with lactulose during the same time period reverted it in 40.0% and 69.1% of cases[39]. Similar results were reported with rifaximin as a therapy in a different population of patients with MHE after 2 wk of follow-up. Reversion was reached in 57% of the patients, and when the follow-up was extended to 8 wk, reversion was observed in 75.5%. The group without this treatment reverted HE in 18% and 20% of the patients after 2 and 8 wk, respectively[56]. Response to an 8-wk treatment according to the normalization of the CFF values happened in 6.5% of the patients who underwent treatment *vs* 2.28% in patients included in the placebo group[40].

In a study including subjects with SIBO and MHE, a reversion was found in 42.3% of these patients after a week of rifaximin treatment; however, this result was not contrasted against a control group[27]. A reduction in the mean ammonemia of 24.22% with respect to the basal concentrations was found in a population with similar characteristics, while in patients with MHE and no SIBO there was a reversion in 18.5% after a week of treatment[27]. In yet another study in subjects where the SIBO status was not specified, ammonemia following an 8-wk treatment with rifaximin decreased 7%[61]. A quantitative improvement in terms of scores for QOL were also observed in patients with MHE treated with rifaximin[49,56].

Some studies that evaluated specific endpoints following the suspension of rifaximin and lactulose in patients originally treated for MHE did not find a difference on the rate of OHE development (7.14% *vs* 7.89%)[56,59,62].

Until now, the use of rifaximin has been associated with epigastric discomfort and vomiting in a few patients[56].

**DISCUSSION**

Prevention and treatment of MHE have been the subjects of many clinical trials. However, the lack of a standard of reference for its diagnosis, the impossibility of observing the impact of a simple maneuver over the reversion of MHE or surrogate variables, and the inclusion of multiple endpoint variables to evaluate the effects of these therapies represent challenges for their overall analysis[63]. Thus, result interpretation of each one of the studies should consider the diagnostic tool that was used, the heterogeneity of the patients regarding their demographic data, the level of schooling, history of previous decompensation, previous episodes of encephalopathy, the hepatic functional reserve, the dietary plan or the indication of concurrent treatments accompanying the experimental treatment, as well as the risk factors that predispose to MHE, such as hyponatremia, sarcopenia, hyperammonemia, the presence of SIBO or dysbiosis, because each one of these factors may potentially modify the novel treatment outcome[7,19,21,23,58].

Regarding the outcome, the assessment of the MHE reversion or the incidence of OHE, when performed through standardized tests, may report clinical utility. However, when results are referred as surrogate variables, such as the improvement in raw values of some psychometric tests, the decrease in blood ammonia concentrations, the changes in the prevalence of SIBO or qualitative data on microbiota in patients with MHE, the real impact on these variables are difficult to interpret. To date, few studies include outcomes related to changes in QOL and mortality.

**CONCLUSION**

There are currently different alternatives for the treatment of MHE. Prevention should probably be based on diets that provide adequate energy, protein, dietary fiber, and food sources for probiotics to enhance their therapeutic potential without causing the side effects of pharmacological therapies and avoiding the development of sarcopenia. The treatment for the reversion of MHE and its secondary prevention should be tailored for each individual and use pharmacological options of proven efficacy such as lactulose or rifaximin. The implementation of randomized clinical trials that establish the optimal duration of the treatment and its impact on the QOL and job performance as well as the analysis of the cost-benefit of every treatment for MHE are warranted.

**ACKNOWLEDGEMENTS**

We thank Susan Drier Jonas Sorgi and Carole Bernard by support in the English edition and style correction. Marlene López thanks the Doctor´s Program in Health Sciences from the Universidad Nacional Autónoma de México (UNAM), the National Council of Science and Technology (CONACyT), for the scholarship received.

**REFERENCES**

1 **Amodio P**, Campagna F, Olianas S, Iannizzi P, Mapelli D, Penzo M, Angeli P, Gatta A. Detection of minimal hepatic encephalopathy: normalization and optimization of the Psychometric Hepatic Encephalopathy Score. A neuropsychological and quantified EEG study. *J Hepatol* 2008; **49**: 346-353 [PMID: 18602716 DOI: 10.1016/j.jhep.2008.04.022]

2 **Romero Gómez M**, Córdoba J, Jover R, del Olmo J, Fernández A, Flavià M, Compañy L, Poveda MJ, Felipo V; Red Nacional de Investigación en Encefalopatía Hepática. [Normality tables in the Spanish population for psychometric tests used in the diagnosis of minimal hepatic encephalopathy]. *Med Clin (Barc)* 2006; **127**: 246-249 [PMID: 16942726 DOI: 10.1157/13091264]

3 **Weissenborn K**, Ennen JC, Schomerus H, Rückert N, Hecker H. Neuropsychological characterization of hepatic encephalopathy. *J Hepatol* 2001; **34**: 768-773 [PMID: 11434627 DOI: 10.1016/S0168-8278(01)00026-5]

4 **Sharma P**, Sharma BC, Puri V, Sarin SK. Critical flicker frequency: diagnostic tool for minimal hepatic encephalopathy. *J Hepatol* 2007; **47**: 67-73 [PMID: 17459511 DOI: 10.1016/j.jhep.2007.02.022]

5 **Romero-Gómez M**, Córdoba J, Jover R, del Olmo JA, Ramírez M, Rey R, de Madaria E, Montoliu C, Nuñez D, Flavia M, Compañy L, Rodrigo JM, Felipo V. Value of the critical flicker frequency in patients with minimal hepatic encephalopathy. *Hepatology* 2007; **45**: 879-885 [PMID: 17393525 DOI: 10.1002/hep.21586]

6 **Mina A**, Moran S, Ortiz-Olvera N, Mera R, Uribe M. Prevalence of minimal hepatic encephalopathy and quality of life in patients with decompensated cirrhosis. *Hepatol Res* 2014; **44**: E92-E99 [PMID: 24033755 DOI: 10.1111/hepr.12227]

7 **Merli M**, Giusto M, Lucidi C, Giannelli V, Pentassuglio I, Di Gregorio V, Lattanzi B, Riggio O. Muscle depletion increases the risk of overt and minimal hepatic encephalopathy: results of a prospective study. *Metab Brain Dis* 2013; **28**: 281-284 [PMID: 23224378 DOI: 10.1007/s11011-012-9365-z]

8 **Duarte-Rojo A**, Estradas J, Hernández-Ramos R, Ponce-de-León S, Córdoba J, Torre A. Validation of the psychometric hepatic encephalopathy score (PHES) for identifying patients with minimal hepatic encephalopathy. *Dig Dis Sci* 2011; **56**: 3014-3023 [PMID: 21461913 DOI: 10.1007/s10620-011-1684-0]

9 **Sharma P**, Sharma BC, Agrawal A, Sarin SK. Primary prophylaxis of overt hepatic encephalopathy in patients with cirrhosis: an open labeled randomized controlled trial of lactulose versusno lactulose. *J Gastroenterol Hepatol* 2012; **27**: 1329-1335 [PMID: 22606978 DOI: 10.1111/j.1440-1746.2012.07186.x]

10 **Les I**, Doval E, García-Martínez R, Planas M, Cárdenas G, Gómez P, Flavià M, Jacas C, Mínguez B, Vergara M, Soriano G, Vila C, Esteban R, Córdoba J. Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study. *Am J Gastroenterol* 2011; **106**: 1081-1088 [PMID: 21326220 DOI: 10.1038/ajg.2011.9]

11 **Sharma BC**, Sharma P, Agrawal A, Sarin SK. Secondary prophylaxis of hepatic encephalopathy: an open-label randomized controlled trial of lactulose versus placebo. *Gastroenterology* 2009; **137**: 885-891, 891.e1 [PMID: 19501587 DOI: 10.1053/j.gastro.2009.05.056]

12 **Hartmann IJ**, Groeneweg M, Quero JC, Beijeman SJ, de Man RA, Hop WC, Schalm SW. The prognostic significance of subclinical hepatic encephalopathy. *Am J Gastroenterol* 2000; **95**: 2029-2034 [PMID: 10950053 DOI: 10.1111/j.1572-0241.2000.02265.x]

13 **Bajaj JS**, Saeian K, Schubert CM, Hafeezullah M, Franco J, Varma RR, Gibson DP, Hoffmann RG, Stravitz RT, Heuman DM, Sterling RK, Shiffman M, Topaz A, Boyett S, Bell D, Sanyal AJ. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. *Hepatology* 2009; **50**: 1175-1183 [PMID: 19670416 DOI: 10.1002/hep.23128]

14 **Bajaj JS**, Pinkerton SD, Sanyal AJ, Heuman DM. Diagnosis and treatment of minimal hepatic encephalopathy to prevent motor vehicle accidents: a cost-effectiveness analysis. *Hepatology* 2012; **55**: 1164-1171 [PMID: 22135042 DOI: 10.1002/hep.25507]

15 **Ortiz M**, Jacas C, Córdoba J. Minimal hepatic encephalopathy: diagnosis, clinical significance and recommendations. *J Hepatol* 2005; **42 Suppl**: S45-S53 [PMID: 15777572 DOI: 10.1016/j.jhep.2004.11.028]

16 **Rose CF**, Amodio P, Bajaj JS, Dhiman RK, Montagnese S, Taylor-Robinson SD, Vilstrup H, Jalan R. Hepatic encephalopathy: Novel insights into classification, pathophysiology and therapy. *J Hepatol* 2020; **73**: 1526-1547 [PMID: 33097308 DOI: 10.1016/j.jhep.2020.07.013]

17 **Han W**, Zhang H, Han Y, Duan Z. Cognition-tracking-based strategies for diagnosis and treatment of minimal hepatic encephalopathy. *Metab Brain Dis* 2020; **35**: 869-881 [PMID: 32495311 DOI: 10.1007/s11011-020-00539-w]

18 **Lockwood AH**, Yap EW, Wong WH. Cerebral ammonia metabolism in patients with severe liver disease and minimal hepatic encephalopathy. *J Cereb Blood Flow Metab* 1991; **11**: 337-341 [PMID: 1997506 DOI: 10.1038/jcbfm.1991.67]

19 **Sharma P**, Sharma BC. Predictors of minimal hepatic encephalopathy in patients with cirrhosis. *Saudi J Gastroenterol* 2010; **16**: 181-187 [PMID: 20616413 DOI: 10.4103/1319-3767.65189]

20 **Schulz C**, Schütte K, Reisener N, Voss J, Malfertheiner P. Prevalence of Helicobacter pylori Infection in Patients with Minimal Hepatic Encephalopathy. *J Gastrointestin Liver Dis* 2016; **25**: 191-195 [PMID: 27308650 DOI: 10.15403/jgld.2014.1121.252.hpy]

21 **Hanai T**, Shiraki M, Watanabe S, Kochi T, Imai K, Suetsugu A, Takai K, Moriwaki H, Shimizu M. Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis. *Hepatol Res* 2017; **47**: 1359-1367 [PMID: 28199774 DOI: 10.1111/hepr.12873]

22 **Zhang Y**, Feng Y, Cao B, Tian Q. The effect of small intestinal bacterial overgrowth on minimal hepatic encephalopathy in patients with cirrhosis. *Arch Med Sci* 2016; **12**: 592-596 [PMID: 27279853 DOI: 10.5114/aoms.2015.55675]

23 **Nardelli S**, Lattanzi B, Merli M, Farcomeni A, Gioia S, Ridola L, Riggio O. Muscle Alterations Are Associated With Minimal and Overt Hepatic Encephalopathy in Patients With Liver Cirrhosis. *Hepatology* 2019; **70**: 1704-1713 [PMID: 31038758 DOI: 10.1002/hep.30692]

24 **Agrawal A**, Gupta A, Chandra M, Koowar S. Role of Helicobacter pylori infection in the pathogenesis of minimal hepatic encephalopathy and effect of its eradication. *Indian J Gastroenterol* 2011; **30**: 29-32 [PMID: 21416318 DOI: 10.1007/s12664-011-0087-7]

25 **Gupta A**, Dhiman RK, Kumari S, Rana S, Agarwal R, Duseja A, Chawla Y. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. *J Hepatol* 2010; **53**: 849-855 [PMID: 20675008 DOI: 10.1016/j.jhep.2010.05.017]

26 **Lunia MK**, Sharma BC, Sachdeva S. Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy. *Hepatol Int* 2013; **7**: 268-273 [PMID: 26201641 DOI: 10.1007/s12072-012-9360-9]

27 **Zhang Y**, Feng Y, Cao B, Tian Q. Effects of SIBO and rifaximin therapy on MHE caused by hepatic cirrhosis. *Int J Clin Exp Med* 2015; **8**: 2954-2957 [PMID: 25932262]

28 **Bajaj JS**, Torre A, Fagan A, Rojas LM, Gavis E, De Leon O, Fuchs M, Escalona NI, White MB, Sikaroodi M, Gillevet PM. Gut microbiota are associated with minimal hepatic encephalopathy (MHE) in cirrhosis regardless of country of origin. *Gastroenterology* 2020; **158**: S-1352 [DOI: 10.1016/S0016-5085(20)34051-8]

29 **Liu Q**, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. *Hepatology* 2004; **39**: 1441-1449 [PMID: 15122774 DOI: 10.1002/hep.20194]

30 **Shawcross DL**, Wright G, Olde Damink SW, Jalan R. Role of ammonia and inflammation in minimal hepatic encephalopathy. *Metab Brain Dis* 2007; **22**: 125-138 [PMID: 17260161 DOI: 10.1007/s11011-006-9042-1]

31 **Li W**, Li N, Wang R, Li Q, Wu H. Interferon gamma, interleukin-6, and -17a levels were correlated with minimal hepatic encephalopathy in HBV patients. *Hepatol Int* 2015; **9**: 218-223 [PMID: 25794550 DOI: 10.1007/s12072-015-9610-8]

32 **Montoliu C**, Piedrafita B, Serra MA, del Olmo JA, Urios A, Rodrigo JM, Felipo V. IL-6 and IL-18 in blood may discriminate cirrhotic patients with and without minimal hepatic encephalopathy. *J Clin Gastroenterol* 2009; **43**: 272-279 [PMID: 18562979 DOI: 10.1097/MCG.0b013e31815e7f58]

33 **Maharshi S**, Sharma BC, Sachdeva S, Srivastava S, Sharma P. Efficacy of Nutritional Therapy for Patients With Cirrhosis and Minimal Hepatic Encephalopathy in a Randomized Trial. *Clin Gastroenterol Hepatol* 2016; **14**: 454-460.e3; quiz e33 [PMID: 26453952 DOI: 10.1016/j.cgh.2015.09.028]

34 **Bajaj JS**, Heuman DM, Hylemon PB, Sanyal AJ, Puri P, Sterling RK, Luketic V, Stravitz RT, Siddiqui MS, Fuchs M, Thacker LR, Wade JB, Daita K, Sistrun S, White MB, Noble NA, Thorpe C, Kakiyama G, Pandak WM, Sikaroodi M, Gillevet PM. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. *Aliment Pharmacol Ther* 2014; **39**: 1113-1125 [PMID: 24628464 DOI: 10.1111/apt.12695]

35 **Egberts EH**, Schomerus H, Hamster W, Jürgens P. Branched chain amino acids in the treatment of latent portosystemic encephalopathy. A double-blind placebo-controlled crossover study. *Gastroenterology* 1985; **88**: 887-895 [PMID: 3882509 DOI: 10.1016/s0016-5085(85)80004-4]

36 **Ndraha S**, Hasan I, Simadibrata M. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. *Acta Med Indones* 2011; **43**: 18-22 [PMID: 21339541]

37 **Kato A**, Tanaka H, Kawaguchi T, Kanazawa H, Iwasa M, Sakaida I, Moriwaki H, Murawaki Y, Suzuki K, Okita K. Nutritional management contributes to improvement in minimal hepatic encephalopathy and quality of life in patients with liver cirrhosis: A preliminary, prospective, open-label study. *Hepatol Res* 2013; **43**: 452-458 [PMID: 22994429 DOI: 10.1111/j.1872-034X.2012.01092.x]

38 **Chatauret N**, Butterworth RF. Effects of liver failure on inter-organ trafficking of ammonia: implications for the treatment of hepatic encephalopathy. *J Gastroenterol Hepatol* 2004; **19**: S219-S223 [DOI: 10.1111/j.1440-1746.2004.03648.x]

39 **Mittal VV**, Sharma BC, Sharma P, Sarin SK. A randomized controlled trial comparing lactulose, probiotics, and L-ornithine L-aspartate in treatment of minimal hepatic encephalopathy. *Eur J Gastroenterol Hepatol* 2011; **23**: 725-732 [PMID: 21646910 DOI: 10.1097/MEG.0b013e32834696f5]

40 **Sharma K**, Pant S, Misra S, Dwivedi M, Misra A, Narang S, Tewari R, Bhadoria AS. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: a randomized controlled trial. *Saudi J Gastroenterol* 2014; **20**: 225-232 [PMID: 25038208 DOI: 10.4103/1319-3767.136975]

41 **Kircheis G**, Nilius R, Held C, Berndt H, Buchner M, Görtelmeyer R, Hendricks R, Krüger B, Kuklinski B, Meister H, Otto HJ, Rink C, Rösch W, Stauch S. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study. *Hepatology* 1997; **25**: 1351-1360 [PMID: 9185752 DOI: 10.1002/hep.510250609]

42 **Douglas LC**, Sanders ME. Probiotics and prebiotics in dietetics practice. *J Am Diet Assoc* 2008; **108**: 510-521 [PMID: 18313433 DOI: 10.1016/j.jada.2007.12.009]

43 **Rai R**, Saraswat VA, Dhiman RK. Gut microbiota: its role in hepatic encephalopathy. *J Clin Exp Hepatol* 2015; **5**: S29-S36 [PMID: 26041954 DOI: 10.1016/j.jceh.2014.12.003]

44 **Bajaj JS**, Saeian K, Christensen KM, Hafeezullah M, Varma RR, Franco J, Pleuss JA, Krakower G, Hoffmann RG, Binion DG. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. *Am J Gastroenterol* 2008; **103**: 1707-1715 [PMID: 18691193 DOI: 10.1111/j.1572-0241.2008.01861.x]

45 **Malaguarnera M**, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: a randomized, double-blind, placebo-controlled study. *Dig Dis Sci* 2007; **52**: 3259-3265 [PMID: 17393330 DOI: 10.1007/s10620-006-9687-y]

46 **Lunia MK**, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. *Clin Gastroenterol Hepatol* 2014; **12**: 1003-8.e1 [PMID: 24246768 DOI: 10.1016/j.cgh.2013.11.006]

47 **Prasad S**, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. *Hepatology* 2007; **45**: 549-559 [PMID: 17326150 DOI: 10.1002/hep.21533]

48 **Ziada DH**, Soliman HH, El Yamany SA, Hamisa MF, Hasan AM. Can Lactobacillus acidophilus improve minimal hepatic encephalopathy? A neurometabolite study using magnetic resonance spectroscopy. *Arab J Gastroenterol* 2013; **14**: 116-122 [PMID: 24206740 DOI: 10.1016/j.ajg.2013.08.002]

49 **Wang JY**, Bajaj JS, Wang JB, Shang J, Zhou XM, Guo XL, Zhu X, Meng LN, Jiang HX, Mi YQ, Xu JM, Yang JH, Wang BS, Zhang NP. Lactulose improves cognition, quality of life, and gut microbiota in minimal hepatic encephalopathy: A multicenter, randomized controlled trial. *J Dig Dis* 2019; **20**: 547-556 [PMID: 31448533 DOI: 10.1111/1751-2980.12816]

50 **Sharma P**, Sharma BC, Puri V, Sarin SK. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. *Eur J Gastroenterol Hepatol* 2008; **20**: 506-511 [PMID: 18467909 DOI: 10.1097/MEG.0b013e3282f3e6f5]

51 **Dhiman RK**, Sawhney MS, Chawla YK, Das G, Ram S, Dilawari JB. Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy. *Dig Dis Sci* 2000; **45**: 1549-1552 [PMID: 11007104 DOI: 10.1023/a:1005556826152]

52 **Jain L**, Sharma BC, Srivastava S, Puri SK, Sharma P, Sarin S. Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy. *J Gastroenterol Hepatol* 2013; **28**: 1187-1193 [PMID: 23425082 DOI: 10.1111/jgh.12160]

53 **Singh J**, Sharma BC, Maharshi S, Puri V, Srivastava S. Spectral electroencephalogram in liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy. *J Gastroenterol Hepatol* 2016; **31**: 1203-1209 [PMID: 26716736 DOI: 10.1111/jgh.13283]

54 **Singh J**, Sharma BC, Puri V, Sachdeva S, Srivastava S. Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy. *Metab Brain Dis* 2017; **32**: 595-605 [PMID: 28070704 DOI: 10.1007/s11011-016-9944-5]

55 **Horsmans Y**, Solbreux PM, Daenens C, Desager JP, Geubel AP. Lactulose improves psychometric testing in cirrhotic patients with subclinical encephalopathy. *Aliment Pharmacol Ther* 1997; **11**: 165-170 [PMID: 9042989 DOI: 10.1046/j.1365-2036.1997.118289000.x]

56 **Sidhu SS**, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial). *Am J Gastroenterol* 2011; **106**: 307-316 [PMID: 21157444 DOI: 10.1038/ajg.2010.455]

57 **Agrawal A**, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. *Am J Gastroenterol* 2012; **107**: 1043-1050 [PMID: 22710579 DOI: 10.1038/ajg.2012.113]

58 **Sharma P**, Sharma BC, Sarin SK. Predictors of nonresponse to lactulose for minimal hepatic encephalopathy in patients with cirrhosis. *Liver Int* 2009; **29**: 1365-1371 [PMID: 19555401 DOI: 10.1111/j.1478-3231.2009.02067.x]

59 **Sidhu SS**, Goyal O, Parker RA, Kishore H, Sood A. Rifaximin vs. lactulose in treatment of minimal hepatic encephalopathy. *Liver Int* 2016; **36**: 378-385 [PMID: 26201713 DOI: 10.1111/liv.12921]

60 **Morgan MY**, Alonso M, Stanger LC. Lactitol and lactulose for the treatment of subclinical hepatic encephalopathy in cirrhotic patients. A randomised, cross-over study. *J Hepatol* 1989; **8**: 208-217 [PMID: 2654285 DOI: 10.1016/0168-8278(89)90009-3]

61 **Bajaj JS**, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, Fuchs M, Ridlon JM, Daita K, Monteith P, Noble NA, White MB, Fisher A, Sikaroodi M, Rangwala H, Gillevet PM. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. *PLoS One* 2013; **8**: e60042 [PMID: 23565181 DOI: 10.1371/journal.pone.0060042]

62 **Goyal O**, Sidhu SS, Kishore H. Minimal hepatic encephalopathy in cirrhosis- how long to treat? *Ann Hepatol* 2017; **16**: 115-122 [PMID: 28051800 DOI: 10.5604/16652681.1226822]

63 **Saab S**, Suraweera D, Au J, Saab EG, Alper TS, Tong MJ. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. *Liver Int* 2016; **36**: 986-993 [PMID: 26561214 DOI: 10.1111/liv.13005]

64 **Malaguarnera M**, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, Pennisi G, Rampello L. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. *Dig Dis Sci* 2008; **53**: 3018-3025 [PMID: 18357530 DOI: 10.1007/s10620-008-0238-6]

65 **Dhiman RK**, Rana B, Agrawal S, Garg A, Chopra M, Thumburu KK, Khattri A, Malhotra S, Duseja A, Chawla YK. Probiotic VSL#3 reduces liver disease severity and hospitalization in patients with cirrhosis: a randomized, controlled trial. *Gastroenterology* 2014; **147**: 1327-1337.e3 [PMID: 25450083 DOI: 10.1053/j.gastro.2014.08.031]

66 **Ahluwalia V**, Wade JB, Heuman DM, Hammeke TA, Sanyal AJ, Sterling RK, Stravitz RT, Luketic V, Siddiqui MS, Puri P, Fuchs M, Lennon MJ, Kraft KA, Gilles H, White MB, Noble NA, Bajaj JS. Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with Rifaximin in Cirrhosis: implications for the gut-liver-brain axis. *Metab Brain Dis* 2014; **29**: 1017-1025 [PMID: 24590688 DOI: 10.1007/s11011-014-9507-6]

67 **Bajaj JS**, Heuman DM, Wade JB, Gibson DP, Saeian K, Wegelin JA, Hafeezullah M, Bell DE, Sterling RK, Stravitz RT, Fuchs M, Luketic V, Sanyal AJ. Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy. *Gastroenterology* 2011; **140**: 478-487.e1 [PMID: 20849805 DOI: 10.1053/j.gastro.2010.08.061]

**Footnotes**

**Conflict-of-interest statement:** The authors have no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Corresponding Author's Membership in Professional Societies:** American Gastroenterological Association, No. 167486.

**Peer-review started:** January 29, 2021

**First decision:** February 24, 2021

**Article in press:**

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** Mexico

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

**P-Reviewer:** Zhang WH **S-Editor:** Gong ZM **L-Editor:** Filipodia **P-Editor:**

**Table 1 Classification of the different stages of hepatic encephalopathy**

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Diagnostic criteria | Classification stages | | | | | |
| ISHEN | Unimpaired | Covert hepatic encephalopathy | | Overt hepatic encephalopathy | | |
| WHC |  | MHE | Grade I | Grade II | Grade III | Grade IV |
|  | No encephalopathy, no history of OHE | Imperceptible cognitive alterations during routine clinical examination | Trivial lack of awareness  Euphoria or anxiety  Shortened attention span  Impairment of addition or subtraction  Altered sleep rhythm | Lethargy or apathy  Disorientation for time  Obvious personality change  Inappropriate behavior  Dyspraxia  asterixis | Somnolence to semistupor  Responsive to stimuli  Confused  Gross disorientation  Bizarre behavior | Coma |

ISHEN: International Society for Hepatic Encephalopathy and Nitrogen Metabolism; MHE: Minimal hepatic encephalopathy; OHE: Overt hepatic encephalopathy; WHC: West Haven Criteria.

**Table 2 Diagnostic tools for the diagnosis of minimal hepatic encephalopathy**

|  |  |
| --- | --- |
| Test type | Test approach to differentiate MHE form unimpaired subjects |
| Formal neuropsychological  Assessment | No standard battery for MHE has been designed, but could include test of attention, executive function, psychomotor ability, and speed information processing to evaluate cognition, and mental activity. |
| Neuropsychological | EEG: Detect changes in cortical cerebral activity.  Evoked potentials: Measurement of firing patterns of single cells or cell clusters. |
| Computerised | SCAN test: Measures speed and accuracy to perform a digit recognition memory task of increasing complexity.  CFF: Degree of vigilance.  CRT: Relies on the repeated registration of the motor reaction time to auditory stimuli. Measures the stability of the reaction time.  Stroop test: Evaluates psychomotor speed and cognitive flexibility.  ICT: Test of response inhibition and working memory. |
| Imaging | MRI: Through mean kurtosis values, evaluates six regions of interest, and amplitude of low frequency fluctuation values, which correlate with PHES values. |
| Short neuropsychological batteries | PHES: Evaluates cognitive/psychomotor processing speed and visuomotor coordination (NCT-A, NCT-B, SDT, LTT, DST).  ANT: Cognitive function related to prefrontal anterior/cortex cortical areas. |

ANT: Animal naming test; CFF: Critical flicker frequency; CRT: Continuous reaction time; DST: Digit symbol test; EEG: Electroencephalogram; ICT: Inhibitory control test; LTT: Line tracing test; MHE: minimal hepatic encephalopathy; MRI: Magnetic resonance imaging; NCT-A: Number connection test A; NCT-B: Number connection test B; PHES: Psychometric hepatic encephalopathy score; SDT: Serial dotting test.

**Table 3 Published studies using several options for minimal hepatic encephalopathy treatment: Diet, branched-chain amino acids or L-ornithine-L-aspartate supplementation, and probiotics/symbiotics**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Ref. | Study type | follow-up (wk) | MHE diagnosis | Active treatment (s) | Objectives | Patients (*n*) | Main results/impact measures |
| No history of OHE1 |  |  |  |  |  |  |  |
| Kato *et al*[37], 2012 | Quasi-experimental | 8 | NCT-A, NCT-B, BDT, DST | 30-35 Kcal + 1.0-1.5 g/kg of protein/d3,4 | Reversal of MHE | 19 | 11/19 (57.8%) recovered at 4 wk, and 13/19 (68.4%) at 8 wk8 |
| Maharshi *et al*[33], 2016 | Randomized2 | 24 | NCT-A/FCT-A, NCT-B/FCT-B, DST, LTT, SDT | Nutritional education/no nutritional therapy3,5 | Reversal of MHE | 60/60 | 27/38 (71.1%) *vs* 8/35 (22.8%); 27/60 (45%) *vs* 8/60 (13.3%), when considering PPS and ITT analysis. |
| Malaguarnera *et al*[64], 2008 | Randomized, double-blind | 13 | NCT-A, NCT-B, BDT, SDT, TMT, AVL, EGG | Acetyl-L-carnitine /placebo5 | Cognitive scores7 | 60/55 | Changes of mean values in at least 20.71% to 32.79% respect to basal values8 |
| Bajaj *et al*[34], 2014 | Randomized, double-blind | 8 | NCT-A, NCT-B, DST/BDT | LGG/placebo | Psychometric scores7 | 18/19 | Improvement from 1.02% to 15.89% from baseline values |
| Bajaj *et al*[44], 2008 | Randomized2 | 8 | NCT-A, BDT, DST | Probiotic yogurt/no treatment4,5 | Reversal of MHE | 17/8 | ITT analysis: Reversal in 12/17 (70.58%) *vs* 0/7 (0%) |
| Mittal *et al*[39], 2011 | Randomized2 | 12 | NCT-A/FCT-A, NCT-B/FCT-B, BDT, PC | Lactulose/VSL#3, LOLA/no treatment | Reversal of MHE | 40/40/40/40 | ITT analysis: Reversal of 4 (10%) in no treatment group, 19 (47.5%), 14 (35%) and 14 (35%) |
| Possible history of OHE1 |  |  |  |  |  |  |  |
| Egberts *et al*[35], 1985 | Crossover, double blind | 6 | EGG, DST, MVT-B | BCAAs/placebo | Psychometry and EGG | 11/11 | Improvement in psychometric test from 0 to 13.63% respect to basal values in DST8 |
| Ndraha *et al*[36], 2011 | Double blind, randomized | 2 | CFF | BCAAs + LOLA/BCAAs4 | CFF | 17/17 | Improvement in CFF 7.0% and 1.96% values (Hz), respect to baseline |
| Kircheis *et al*[41], 1997 | Randomized, double-blind | 1 | NCT-A | LOLA infusion vs Placebo5 | Psychometry7 | 26/27 | Improvement in mean time to respond NCT-A from baseline (29% *vs* 9.73%) |
| Liu *et al*[29], 2004 | Randomized2 | 4 | NCT, BAEP | Symbiotics + fermentable fibers/fermentable fibers/placebo4,5 | Reversal of MHE7 | 20/20/15 | Reversal of 50% in symbiotic group, 50% in fermentable fibers group and 13% in placebo. Not statistically significant until compression of treatment groups *vs* placebo (*p* = 0.03)9 |
| Dhiman *et al*[65], 2014 | Double blind, randomized | 24 | NCT-A/FCT-A, NCT-B, SDT, DST, LTT | VSL#3/placebo | Psychometric scores7 | 16/13 | Mean psychometric scores before and after probiotics -9.9 (-13.3- to -6.5) *vs* -5.7 (-8.4 to 2.9) *p* = 0.014. Proportion of patients with scores < -5 did not change in either group10 |
| Malaguarnera *et al*[45], 2007 | Randomized, double-blind | 17 | TMT-A, TMT-B, BDT, MMSE | *Bifidobacterium longum* + FOS/placebo5 | Psychometry | 30/30 | No statistical or clinical change was found respect to basal values at, 30, 60, 90 and 120 d |
| Ziada *et al*[48], 2013 | Randomized2 | 4 | NCT-A, DST, SDT | Lactulose/L, acidophilus/control5,6 | Psychometry | 24/26/25 | Normalization of test occurred in 13/24 (54.2%), 14/26 (53.8%), and 3/25 (12%) |

1Studies in which the clinical history to the OHE events is specified or no is specified within the inclusion criteria; 2unblinded study; 3the effect of other treatments for MHE was not studied; 4Treatment compliance was not assessed in one or different group of treatments; 5diet was not standardized together with the suggested treatment; 6the treatment that the control group received was not specified; 7secondary objectives within the study; 8the analysis was performed within the same group (before–after treatment) despite the study design; 9addition of the effect of two maneuvers; 10MHE reversion was not measured. AVL: Auditory verbal learning test; BAEP: Brainstem auditory evoked potential; BCAAs: Branched-chain amino acids; BDT: Block design test; CFF: Critical flicker frequency; DST: Digit symbol test; EEG: Electroencephalogram; FCT-A: Figure connection test A; FCT-B: Figure connection test B; ITT: Intention to treat; LOLA: L-ornithine-L-aspartate; LTT: Line tracing test; MHE: Minimal hepatic encephalopathy; MMSE: Mini mental state examination; MVT-B: Multiple choice vocabulary test B; NCT-A: Number connection test A; NCT-B: Number connection test B; PC: Picture completion; PPS: Per Protocol Analysis Set; SDT: Serial dotting test; TMT: Trail making test; TMT-A: Trail making test A; TMT-B: Trail making test B.

**Table 4 Published studies using non-absorbable disaccharides for minimal hepatic encephalopathy treatment**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study type** | **follow-up (wk)** | **MHE diagnosis** | **Active treatment (s)** | **Objectives** | **Patients (*n*)** | **Main results/impact measures** |
| No history of OHE1 |  |  |  |  |  |  |  |
| Prasad *et al*[47], 2007 | Randomized2 | 12 | NCT-A/FCT-A, NCT-B/FCT-B, PCT, BDT | Lactulose *vs* no treatment | Psychometry | 31/30 | ITT analysis: Improvement in 20/31 (64.5%) *vs* 2/30 (6.7%); NNT:2 |
| Horsmans *et al*[55], 1997 | Randomized, double-blind | 2 | NCT, RTT. | Lactulose *vs* lactose as placebo4,5 | Psychometry | 7/7 | Improvement in time on Psychometric test on lactulose group respect to basal values.7 Rate of improvement NCT: 5/7 (71.42%) *vs* 1/7 (14.28%); NNT:2 |
| Sharma *et al*[50], 2008 | Randomized2 | 4 | NCT-A/FCT-A, NCT-B/FCT-B, P300ERP | Lactulose, probiotics, and lactulose + probiotics5 | Psychometry, P300ERP6 | 35/35/35 | Normalization in 17/31 (54.8%), 16/31 (51.6%), and 17/30 (56.6%) of MHE patients |
| Morgan *et al*[60], 1989 | Cross-over, randomized | 83 | EEG, NCT, DST, DCT | Lactulose *vs* lactitol4 | Psychometry | 14/14 | No differences between treatments in median change in psychometric time or scores |
| Possible history of OHE1 |  |  |  |  |  |  |  |
| Dhiman *et al*[51], 2000 | Randomized2 | 12 | NCT-A/FCT-A, NCT-B /FCT-B, PCT, BDT. | Lactulose *vs* no lactulose4 | MHE improvement | 14/12 | Improvement in 8/10 (80.0%) *vs* 0/8 (0.0%), *p* < 0.001)8 |
| Wang *et al*[49], 2019 | Randomized2 | 8 | NCT-A, DST | Lactulose *vs* no lactulose | MHE reversal | 67/31 | ITT analysis: 43/67 (64.2%) *vs* 7/31 (22.6%); NNT: 3  PPS: 41/59 (69.5%) *vs* 6/28 (21.4%); NNT: 2 |

1Studies in which the inclusion criteria comprise patients with clinical history to the overt hepatic encephalopathy events; 2unblinded study; 3washout period of 4-6 wk between treatments; 4Compliance to treatment was not measured in one or the different treatment groups; 5diet was not standardized according to the suggested treatment; 6secondary objectives within the study; 7analysis was performed within the same group (before–after treatment) despite the experimental design; 8Minimal hepatic encephalopathy reversion not measured. BDT: Block design test; DCT: Digit copying test; DST: Digit symbol test; EEG: Electroencephalogram; FCT-A: Figure connection test A; FCT-B: Figure connection test B; ITT: Intention to treat; MHE: Minimal hepatic encephalopathy; NCT: Number connection test; NCT-A: Number connection test A; NCT-B: Number connection test B; NNT: Number needed to treat; OHE: Overt hepatic encephalopathy; PCT: Picture completion test; PPS: Per protocol analysis set; RTT: Race track test.

**Table 5 Published studies using antibiotics for minimal hepatic encephalopathy treatment**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **Ref.** | **Study type** | **follow-up (wk)** | **MHE diagnosis** | **Active treatment (s)** | **Objectives** | **Patients (*n*)** | **Main results/impact measures** |
| No history of OHE1 |  |  |  |  |  |  |  |
| Ahluwalia *et al*[66], 2014 | Quasi-experimental | 8 | NCT-A, NCT-B, DST, BDS, LTT, SDT, ICT | Rifaximin4 | fMRI, ICT, MRS5 | 20 | Changes in ICT, improvement of 12% respect to baseline, indicating a better cognition |
| Bajaj *et al*[61], 2013 | Quasi-experimental | 8 | NCT-A, NCT-B, DST, BDT, LTT | Rifaximin4 | Psychometry5 | 20 | Improvement in NCT-A time (11.8%), NCT-B time (11.8%), DST raw score (9.1%), BDT raw score 0.0%), LTT time (20.7%), LTT errors (39.8%), SDT time (12.3%) from basal values |
| Bajaj *et al*[67], 2011 | Randomized, single-blinded | 8 | NCT-A, DST, BDT, ICT | Rifaximin/placebo4 | Driving performance, psychometry scores | 21/21 | Decrease of 46.6% of total errors respect to baseline in rifaximin group (*p* < 0.001)6  Improvement in NCT-A 91% *vs* 61% (NNT: 4); NCT-B: 81% *vs* 33% (NNT: 2); and ICT lures: 76% *vs* 43% (NNT: 3)7 |
| Sidhu *et al*[59], 2015 | Randomized, non-inferiority trial | 12 | NCT-A, FCT-A, DST, PCT, and BDT | Rifaximin/lactulose | Reversal of MHE | 57/55 | ITT analysis shows a reversal at 2 wk: lactulose 40.0% *vs* rifaximin 52.63% (NNT: 8)  ITT analysis at 3 mo shows reversal in 69.1% and 73.7% of lactulose and rifaximin, (NNT: 22) |
| Goyal *et al*[62], 2017 | Prospective cohort | 24 | NCT-A, FCT-A, DST, PCT, BDT | Previous intake of Rifaximin compared to lactulose3,4 | Maintenance of remission for MHE | 42/38 | Still free of MHE: Rifaximin 42.8% *vs* lactulose 50.0% (NNT: 14) |
| Possible history of OHE1 |  |  |  |  |  |  |  |
| Agrawal *et al*[24], 2011 | Quasi-experimental | 1 | NCT, FTC, LTT. | Clarithromycin, lansoprazole, tinidazole3,4 | Psychometric scores5 | 35 | Improvement in 12.7%, 13.3%, and 18.7% respect to basal mean time in NCT, FCT and LTT, respectively |
| Zhang *et al*[27], 2015 | Quasi-experimental | 5 | NCT-A, NCT-B, DST | Rifaximin 1 wk3,4 | Reversal of MHE | 26 | After a week, reversal present in 11/26 (42.3%) |
| Sidhu *et al*[56], 2011 | Double-blind, randomized | 8 | NCT-A/FCT-A, DST, PCT, BDT | Rifaximin/placebo | Reversal of MHE | 49/45 | Reversal at 2 wk: 57% *vs* 18% (NNT: 3)  At 8 wk: Reversal of 75.5% *vs* 20% (NNT: 2) |
| Sharma *et al*[40], 2014 | Randomized2 | 8 | NCT-A/FCT-A, DST and/ or CFF | LOLA/rifaximin/Probiotics/Placebo4 | Reversal of MHE5 | 31/31/32/30 | ITT analysis: Improvement in CFF values (Hz) from baseline in 11.42%, 6.5%, 8.68%, and 2.28% |

1Studies in which the inclusion criteria comprise patient with clinical history to the overt hepatic encephalopathy events; 2unblinded study; 3Compliance to treatment was not measured in one or the different treatment groups; 4diet was not standardized according to the suggested treatment; 5secondary objectives within the study; 6analysis was performed within the same group (before–after treatment) despite the experimental design; 7Minimal hepatic encephalopathy reversion not measured. BDT: Block design test; CFF: Critical flicker frequency; DST: Digit symbol test; FCT: Figure connection test; FCT-A: Figure connection test A; ICT: Inhibitory Control Test; ITT: Intention to treat: LTT: Line tracing test; MHE: Minimal hepatic encephalopathy; NCT: Number connection test; NCT-A: Number connection test A; NCT-B: Number connection test B; NNT: Number Needed to Treat; OHE: Overt hepatic encephalopathy; PCT: Picture completion test; SDT: Serial dotting test.